Liver Neoplasms Clinical Trial
Official title:
PET/CT-Guided Liver Tumor Ablation: Intraprocedural Assessment of Results Using Ammonia Perfusion PET
In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET
perfusion scans are more useful in helping radiologists determine whether liver tumors were
successfully destroyed by the heating or freezing procedures (ablations) than other scans
currently available to radiologists, such as CT scans and MRI scans.
The currently available scan (usually a CT scan with contrast dye) is not always effective in
showing how completely the tumor has been destroyed. The ammonia PET scan is a different way
of looking at how much tumor has been destroyed. This study will compare the standard scan
(CT scan) with the ammonia PET scan.
The plan for this study involves the non-therapeutic administration of a radiopharmaceutical,
N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation
procedure. The perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure
is performed according to our standard clinical practice and is not itself a research
activity. The use of N-13 ammonia or F-18 fluorodeoxyglucose to image liver perfusion with a
PET scanner is the research portion of the procedure. The patient will receive one or two
doses of N-13 ammonia (10 mCi (millicurie)/dose) for intraprocedural assessment of ablation
results. Not more than two doses will be administered and one or both doses will be
administered on the day of the tumor ablation procedure only. The ammonia perfusion scan will
not be used to change or modify the ablation procedure.
After the screening procedures confirm that that the participant is eligible to participate
in the research study:
- Ammonia Perfusion PET: The participant will be scheduled for the tumor ablation
procedure as part of the participant's routine care. If the participant decided to take
part in this research study, then the participant will have one or two ammonia perfusion
PET scans during the ablation procedure to see if the ablation was successful or not as
compared to standard CT scanning. The ammonia perfusion PET scans are the research part
of the participant's procedure. The rest of the participant's procedure is not research.
The participant will receive one or two doses of the radioactive tracer called N-13
ammonia. This tracer is administered through the same IV (thin tube placed in a vein)
used by the Anesthesiologist to give the participant routine medications that relax the
participant, prevent pain, and allow the participant to sleep during the procedure. This
tracer does not treat the participant's tumor in any way. Instead, the tracer may allow
the radiologist to better see how much of the participant's tumor was destroyed.
- Photographs: Photographs may be taken during the procedure. Care will be taken to ensure
these do not reveal the participant's identity.
- Clinic visits: The investigators routinely see patients after tumor ablation procedures
within one to two weeks after the procedure and then every three months after the
procedure for one to two years, and as needed in the future. Accordingly, the clinic
visits are routine and not an added research commitment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
Not yet recruiting |
NCT03592550 -
The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
|
||
Not yet recruiting |
NCT02521129 -
A New Track Ablation Device for Liver Biopsy: A Feasibility Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02168608 -
Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
|
N/A | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Active, not recruiting |
NCT01177007 -
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
|
Phase 2 | |
Completed |
NCT00788697 -
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
|
Phase 3 | |
Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
Completed |
NCT00094003 -
Study of NS-9 in Patients With Liver Metastases
|
Phase 1 | |
Terminated |
NCT00051532 -
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT00001587 -
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
|
Phase 1 | |
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT03289273 -
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
|
||
Terminated |
NCT03349255 -
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03715517 -
Spinal Anesthesia For Enhanced Recovery After Liver Surgery
|
N/A | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01744054 -
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
|
Phase 1 | |
Active, not recruiting |
NCT02969096 -
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
|
Phase 2 |